=Abstract=
Clinical Analysis of Neuroblastoma
Tae Jin Kim, M.D., Seung Hoon Choi, M.D., Eui Ho Hwang, M.D.
Division of Pediatric Surgery, Yonsei University College of Medicine Seoul, Korea
Neuroblastoma is a solid tumor derived from neural crest cells of the sympathetic nervous system.
It isthe most common extracranial solid tumor in children. Although it has the highest rate of spontaneous regression, it has a bad prognosis. Recent reports indicate a much improved outcomes utilizing the multitreatment approaches and early diagnosis as a result of patient screening. We have studied 42 patients managed in the last decade at the Severance and Y ongdong Severance Hospitals
.The patients were followed until January 1998 and analyzed in terms of age, sex, admission period, stage, diagnostic studies, clinical symptoms, physical findings, oper- ative time, treatment modalities, and survival rate. Twenty eight patients underwent operative procedures, 16 patients had postoperative chemotherapy, and 19 patients had preoperative chemotherapy. Sexual difference was 1.33:1 in favor of males, and 43
%of patients were under one year of age. The patients were initially diagnosed as a result of symptoms and signs.
Anabdominal mass was the most common clinical finding. Eighty six percent of the patients were in advanced stages (>Stage III of INSS). The 2 year survival rate was 59.2
%and the 5 year survival rate was 29
.6 %.Index Words: Neuroblastoma, Chemotherapy
~~£~~~~ ~~~~~~ ~~&1::::- ~~
%~~5!. ¥~~~~t+ ~~~~~~~ ~1&
t:9,
~o}oJ]).i5!.1::::-
7};;<J- ~~ ~Acl %0J= %~ -t}Correspondence; Seung Hoon Choi, M.D., Department of Surgery, Yonsei University College of Medicine, 146-92 Dogok-dollg, Kangnam-Ku., Seoul 135-270, Korea
t+.5~JL l!!J~~, %4-~~1l] %0J=, ii:l~~ qg~
5!. ~£7} ~~t9 ~~] ~o}'?}~ 8-10 %~ j,}7.]
~q, 0l~ ~7PJ-Y1
%0J=
°19.1~ 7}:'<J- !~ Jl~ ,?}01ql.3. ~A~~£1::::- u~l;'!
'4
100'i!- '{:j % 8.7'{:j20 ]t:9,
1OA~] o]~oJ]1::::- ~%q.0]
%0J=~ ~"~-f!:- T5!- 5"1] 0]t"}(90%), ~t"] Ikl] 1]]'Il-oJ]A1 P{:il 'i=fL1S!.! 1:l]%S!.! l.3:15!- Ji..:ilso].:il 91ql. ~
"~-f!:- ~ 70 %7} .1il-7J
t.H
o]uj J 7: ',ilo] -¥---8 y~ oj] A1 7] ~ t"}uj, J 'I.roJ] :g:.~1.J1, 7cl.!f-, l:l]-¥-,T7B ~
t.H
oj] A1 ~,,~ ~l:j-. ~ 7cl5'.. Al].¥. %-f!:- qOJ~"fJAJ~ ~Acl% Ji.O~T.:il 91q, A}~£j:§:} '~VJ%
I..-} E./-1.J1-c % oJ S'.. .5~J1 {i 7<1] --87cl 5'.. Al].¥. % S!.! S % 7]-A}~£j:§:}t"}9, TS!.. Stage I o]l-j- IY-S 9.] JAl]
1]] ;19.]
01
~ 0] oj] T S!.. ~ o1\::l-q. {lt: H
a:j 2-1*"
oj] ~AH1-c
7CH- 7r
50 % 0] AJo] uj4, {i0]S!.! {l"~1) s:.7} DH.q.. HH}~ 7cl.q.. s:.
Pi-
0}, oj] ~7]- 7}.zJ l-j-~'?:l-
7: t"\,l-j-o] q5--87cl5'.. Al]2l%S!.! -"-]li-c q~ %oJS!.! 7cl.q..~H:J y~.Jl} ClJA}{! R~.Jl} :§:}~ R~O] J.Hl-SO].:il 91 S'..l-j- {lBA] {l"~B 7Cl~7]- Pio} 5'..-§- ~]li~%
%~t"}a:js:. .zJ7] "~~%o] ';;t-f!:- ~%o]q. ~1.J1 oJjJ'1:::= ~ ~]li7]-t!oJ]A1 7cl<'fl~ ill]7} JC] "PiA]
~7] uJl~o1] ~.RB :;lo] PiA] ~-f!:- ~1)o]q.
0] oj] A1A}%~ .Jl}71 101;1~ ~]li~ 42ill]S!.! "fJAJ
~l -1f:-~% %t"}a:j 0] ~~9.J "fJAJ OJAJ.Jl} ~]li ClJ~ ~ nj]-f-01] -t!t"}o~ .:il~t"}~q.
19S71;1 1-%1 1~.!J'-El 19971;1 12-%1 31~77}A] ;1 11\1~ ~Al]t:H~J:iL s!'!.Jl}t:H~ Al]l=!~A JtJ~.Jl}
oJ %Al]l=! ~ ~ JtJ ~ 01] 'iJ ~ t"}a:j -"-]li ~ ~-f!:- 42 ua S!.! ~ A}~ t:H AJ S'..S!.. ~ ~ -1f:-'¥', 'i=fL.'] I:l], 'iJ
i'!
7]~, T~AJ, ~AJ ~~ 7]~, o]~~ ~7,1, {l B~
7d
A}, ~ %~ ~ JtJ 7], 'T-~ A]~, 'T-~{i ~ 'T-~-f- :§:}~ R~, ,,~~% %01] r.B"t}o~ 19951;1 1 -%1 ~ 7] ~ S'..S!.. -1f:-~ "t}~S'..uj "}~ {±{k 7]~-f!:~B 17B-%101]Al ~.zJ 9\1 o]~q. 'T-~::' 2SillH]
A1 A]"~t"}~S'..D1 'T-~ {i :§:}~R~::' 19~]0l]A1 A]"~"t}~.:il 'T-~-f- :§:}~R~-f!:- 16ill]01]A1 A]"~t"}
~ q . ,,~~~S!.! "}~ 3':A-c JtJ ~ 7] ~% 3':At"}.:il 7B~~S!.. AJ:§:}~EHI-S!.. A]"~t"}~q.
'i.!·o] 2ill], 67B-%1 1]];10] Sill], JAl] 1]];10] lOill], 3 Al] 1]] ;10] Sill], SAl] 1]] ;10] 9ill], IOA1] u] ;10] 5 r.l] C;;,.:il, 10Al] 0] AJ-O] 2 ill] C;;, cr. ~ 67B-%1 0];1 0] 19%,0]7: 'i=fA}-C 24ua o]~.:il a:jA:::= ISua .2..5!- 'i=fL.']9.] l:l]-c 1.33:1 o]~q.
l..H SfJ CJA] "T'-B "fJ ~- ~AJ S'..S!..-c .1il-.!J'- %:iJl 10ill], .1il-.!J'- %% lOill], A~ A} 7} 3ill], /cl.!J'-%JI1 7]- 3~]~.:il, .1il-iL ~;1, ~~, AJ7]s:. ~~%" ~.!J'
%-:iJl 7]-
ztZf
2 ill] 1Q 0] ~.:il, ~T ~~%"-'€ g,
~~ %%" T%-, Alan.!J'- %-~, ~~, %Z1% % :iJl, ~l:l], {i{lis1~0]
ZfZf
1 ill] 1Qo]~q.oj~~ {jA} ~7,1AJ .1il--¥- %.Jl]7} ISill]5!- 7}.zJ Pi'V:S'..uj,.1il-~ "iJ-%-0] 3ill], /cl-¥- %JI17} 2ill]7}
9J.~.2..uj 0]9.]01]s:. ~~, ~A}, ~~;<J~, T£.,
t"}7.] %-, ~T~~,
n1
t"HHL ~% t:H, 1:l].zJ% t:H,~1--8:t]~0] lill]1Qo]~S'..D1 o]~~ {jA}AJ ';0]
~7,:!0] ili-c 7cl~s:. 9ill]7} 9J.~q.
%,AJ ~~ -f- ~]li ~7] 77}7.] S!.! 7] ~-f!:- 1
T-
o] t"]-7]- 13ill], 17B -%1 0] t"} 7} l4ill]' 37B
-%l
0] t"} 7}6ill], 67B-%1 0]t"}7} 3ill], 11;1 0]t"}7]- 3ill], 3\1 0]
t"}7} lill] 9J.~S'..uj, 7]~% ~'T- ili-c /cl.q..7} 2
ill] 9J. ~ q. %,AJ ~~ -f- 64 %S!.! 7Cl ~01] 9J.
01
A1 -c 17B-%l
0]t.H
01] -"-]li~ ~'V:q.{lB~~ 7a A
}S!..Al-c,
X-ray7d
A}, .1il-.!J'- &.g iI} {j At, CT 5':-c MRI, MIBG Bone Scan, ~'T~A}{jA}, ~~7aA}7} A]"~SO]~c}. ~nj]o1]Al:::=
ClJA}{!~~ {jA}S!..:::= 7'a*E1 B% t£0Jo] 39ill],
&. %iI} {j A}7} 19i1l], t:H.zJ 5:0J ~o] 2 ill]7} 9J.
01
rll L.fl Tl!:" tI tI .z1 q L L 2.. ' - z~ o1TII: EJ "1 q L 2;. 0 aJ-2 o~ 0 01] ~ 01 a,."til-'-- p ~ ~
y
9J.~q. 'iJ!f:!A] "fJAJ JtJC1 {jA}S!..:::= YMA7}2924] 7: 7 ill] ~7}, HYA7} 15 ill] 7: 4 ill] ~-7},
ferritin-f!:- {jA}~- 301] 5'..T ~7}SO]~l:j. AFP::' 3 ill] 7: 1 ill] 7:7]-, NSE-c 1 ill]
7d
A} t"} c;J. S'.. uj 1) AJo]~q.
Table 1. Single or Combination Chemotherapy of Preoperative Period
Regimen Number of cases
VP 16 3
VP 16. ADR 3
VP16. ADR. CDDP 3
ADR. CDDP 2
VP16. CTX. DEXA 1
VCR. CTX. EPI. CDDP 1
VCR.ADR. CTX 1
VP16. EPI. CDDP 1
VCR. CTX 1
VP16. EPI. CDDP 1
CTX.ADR. CDDP 1
ADR: adriamycin. CDDP: cis-platinum. CTX:
cytoxan. DEXA: dexamethasone EPI : epirubicin. VCR: vincristine
6. ~71
~A~]-lE-*~(INSS)oJ] uj-~ ~7]-c stage 10] 2 il11, stage IlIo] 9il11, stage IV7} 27il1] ~Jl stage II .2} stage IV -S ~
iii
~q.
stage IV oJjJ'l ;~Jo ]-¥-5f1-c bone 0] 17il1]£ 7}7-J ~~Jl, lung 8il11, brain 2il1]';0] ~~q.
"T-~~ §j-"§:j-R~.g. 19i11joJP'1 A}%"6"}~Jl VPI6 t!~ .tE-c *~~£ A}%~ 7cH-7} 7}7-J ~~~oj (lE I), "T-~
+
§j-"§:j-R~::'. 16il1joJjAl A}%"6"}~~oj '2'jA] VP16Jlj-q:=
~%% *~~£ A}%~ 7cH-7}100
80
60
40
20
1 Y r 2 Y r 3 Y r
7}~' ~~q(lE 2). "T-~-"j-D-.g. -3j ~~% -"j ii~ ~ 7Cl -'f-oJj-c 3.35± 1.7 -"j-D-°mJl 5:-3.j::;3A}'il- -"jii~~ 7Cl -'f--c 1±0.41 Aj-D-0j~q.
I1 eTI'
~~7j-D-.g. "T-~%-"jii~~.g. :@7.}-c 2L9±9~, ~%R'il% ~.g. :@7.}
-c 21.3±14.7 ~£ -'j'- -;;:- -D-oJj j,}0]7} 'iiJ~q.
8. ~IE ~.il~2~ ()jl~
j,]ii.+ ~-3j::'. 27il1joJj Al 7}~"6"}~~oj 13il1j7}
;'~~"6"}~Jl 14il1j7} A}{]J"6"}~q. 31;:3. O]AJ ;.~~~
:@7.}-c II il1j ~ ~ oj 51;:3. oj AJ ;.~ e ~ 7Cl-'f--c 8 il1j
£ Al 51;:3. ;.~e%.g. 29.6%~Jl 21;:3. ;.~~%.g.
59.2%~~oj
:;J eTI'
;.~e7j-D-.g. 3.31;:3.0]~q. p},A]~~£
3':-"H!
7Cl-'f-oJj ~:@oJj rJ1~ 7aA}~ S'..-'j'-Table 2. Combination Chemotherapy of Posto- perative Period
Regimen Number of
cases
VP 16. ADR. CDDP 3
VP16.ADR 3
VP16. CTX. CDDP 3
VP16. CTX. ADR. CDDP 2
VP16. EPI. CDDP 1
VCR. CTX.ADR 1
VCR. CTX. EPI. DTIC. CDDP 1
VCR. CTX.DCB 1
ACR. CTX. VCR.CDDP 1
ADR : adriamycin. CDDP: cis-platinum. CT X : cytoxan. DEXA : dexamethasone
EPI : epirubicin. VCR: vincristine. DCB:
dacarbazine
4 Y r 5 Y r
Fig. 1. Actual survival of patients with neuroblastoma after surgery.
A]"E i5}?] CJ:-i5}o:j 0] %-f':- disease free survival 0]
o].\-:! 1(1--i? "'H':·7]Zlo]9ic.]. p'tl I).
{! 7(j .2.l-i] ± %-f':- 1:l].iiL~ '?1'Z1 ~"'E i5}-c ~:@-.Q.
£ 2"'i] o]Y1cJ] 60%7} ~"!li5}Jl lO"'i] o]Y1cJ]-c 97 % 7} ~"!l ~q.Jl i5}1Jj 6, Ai ?}9.] 7(j q-cJ]-c Pi]
0] ~o] 43 %, 10"'1] 0] ~o] 95 %£ 0] ~l- l:l] ~~
~±~ 5!.'X1,c.}. "!l-"-1 1(1-11]~ t+-'T--c ~*liJcJ]-c (staging system) q g:il} ~-f':- "'i]7]'?'] 7]' 9) q. Ch- ildren's cancer 'study groupcJ] Ai 0.Jl ~,-c Evans
~*1iJ (CCS Stage)Jl} St. Jude children's research hospital :il} pediatric oncology groupcJ] J..i 0.-c ~
*1iJ (POG Stage)~ TNM ~*7} ~q. £1~cJ]-c
0]% ~ %~~ ~Ai] ~*IiJ(INSS)I,7% Ll1-i'-~ M
.Jl ~q. J..}q-q o}2}l:l]o}cJjJ,i-c Stage II 30%, Stage III 30 %, Stage IV 35 %, Stage IV -S 5 % 2}
Jl 5!..Jli5}o:j AiA}~-"-1 7(jq-~ 7JO] Stage III~
Stage IV-"-1 :@-?}7} fl'V:.Q.t+ ~3.2.]
'cl
0] 5!..!f1:§}~oj ~-c '?1~ ~cJ]J..i-c Stage III, IV.9.j :@-A}7}
3j.Jl Stage I, II, IV-S :@-;:<.}.9.j l:l] %0]
it
q 8. ~ 5: A l-cJ] J..i ';3-1..'j TAd l:l]-c 1.33: 1 0]9i.Q. oj,"T
~ AJJl} 0]~3j ~{!-f':- *-i'- %:il]7} <>Js:.3j.Q.£fl
'V:q. "T~ Ci:VJ~AJ 2..£ *-i'-%JI17} 7};<.J ~i5}
Jl ~ ~ -i'-ill cJ] at2}J..i qOJ~ ~AJO] t+E.j-t+oj,
!'E~ ~o]cJ] -"-1~ ~AJs:. ~1(1-'it""]cJ] 60-80%cJ]
0]2-c ?;!..Q.£ 7]~SO].Jl ~.Q.oj 0]'3' ~'T- ~o]
cJ] -"-1~ ~, -tl-~% 0] 7]·;<.J ~~ ?;!..Q.£ 7]~~
Jl ~qi,3,4,9. ~l(!-"-1 VMA (vanillylmandelic acid)
~ HVA(homovanillic acid)7} 90 %cJ] J..i AJ%~ oj
~2..oj, ~~cl ferritin, neuron-specific enolase, LDH
~-f':- "!l-"-1 ~i5PJs:., oj]+~ o}-cLl] %Jl7} SO].Jl
~Jql,9 ~1(1-3j ~J..}£-c *-i'- 7',:l#Ei 1(1-"8'- ~Od :ilL ..B..'3' VMA, HVA 7,3J..j-7} 7};<.J *%i5}~tj
?;!. ~ ~ 'T- ~q. N-myc *~?}-"-1 7,:lJ..}7} 3j9i tj ?;!.::: °pllJ}?] o]cJ] Ll1~ 7,:lJ..}7]· 11?] U'V:
gcJ] 7]~i5}::::r~] N-myc *~?}-"-1 ~~o] oj]+cJ]
'?l
~ i5} 71] -tl-o:j i5}:::: ?;!':il} 0] ~ 0] % ~ j.]lis:. ~ 2}~E£ ~.Q.£-C £~ :@-4~~ ~'~o:j~w ~ ..B..7} ~ q. *-i'- 1(1-"8'-~od.g. ~ 1(1-¥-0} 1-] 2}
"!l7]-"-1 ~*cJ] s:. *%i5}o:j j.]li t1JIiJ -"-1 ~:AJ cJ]
j.]-C :;i2..£-c "!l7], ~1(1-A] :@-?}-"-1 t+0]¥-0}1-]
2} ploidy, Shimada "!l7], N-rnyc fr~?}%-~, ~
~cl ferritin ~o] ~-cr~] o]'3'cJ]J..i£ "!l7], t+ 0], N-myc %-~o] 7};<.J '3'..B..~ ~ w% ~qlO. Stage IV-S~ ~lA-"-1 "'~ ~% £ diploid, N-myc *~;:<.}, Unfavorable histology %cJ] at2Pi q..soj 27H-%!
O]AJJI1 0]i5}~ 7(jq-cJ]s:. "'~~%o] ~",*qII {!
1il
£"'1] ± %::: 1970\1 rlllJ};:<'] ~ i5}Li4 s:. 2\1",~~%o] o]';::-cJ]J..i-c 32%, '?1~cJ]J..i-c 29%4 Jl 5!..Jl~ oj]+7} uHq- t+~ %oJo]9i2..t+, a,]~
-"-1 qOJ~ j.]li t1JIiJ -"-1 ~~ £ oj] +7} %,-0};>;].Jl
~c.}12. j.]li-"-1 t1JIiJs:. :@-?}-"-1 t+0]~ N-myc
*
~7j--"-1 ~~, Shimada -"-1 "!l2.]~:§}, ~~cl ferritin cJ] at 4J..i ~
C1
i5}o:j%'-:::
~ Jl} ~ ~ ~ 'T- ~ -c r~]ill~£7} 3j::: :@-7}-i:!'-cJ]J..i-c CCSG-388l%, ill~
s:.7}
it:::
:@-;:<.]·-i:!'-cJ]J..i:::: CCSG-389l-"-1 ~%j.]li~ 3j %i5}o:j ill ~ £7} ,;;!--f':- :@-;:<.}-c 4\1 z} "'~ ~
%0] 100%, Pi]o]i5}o];>;]~ ~7}?] o]""J-"-1 ill~
~?}7} ~-c :@-?}-c 90%, Pi] 0] ""Jo] oj ill~~7}
7} ~-c :@-;:<.}-c 54 %~qlO. a,J-2-o1]-c Stage IV.9.j
:@-7}cJ]J..i ~'T-0]~¥- 0}1-]4 ~~~z}Ai]±o]~
~(PBSCT)~ o]%i5}o:j ~.g. ~Jl}~ ~9iq.Jl 5!.
.Jlso]-cr~l, Eguchi ~-f':- IV 7]-"-1 {!7(j£A~]±%:@- 7}cJ] J..i carboplatinum, VP-16, melphalan ~ ~ ~ o:j i5}.Jl ~ ~ ~ z} Al] C'f 0] ~ ~ %""] cJ] ",,] i5~ -t;}o:j 13 ua '3' 5ua 0] ~~ {!-iiH ~ 7ua '3' 2ua 0] -i'-~{!-iiH ~
~.g. ?;!.2..£ 5!.Jli5}~ql3. ~%..B..liJcJ]s:.
fl:::
~~o] ~oj a,J-2-cJ]-c DNA-topoisomerase I inhi- bitor~ irinotecan(CPT-ll)o] 12f-%! ~ It:il}~ 5!. "?:l 0] %%~~.ll} 0dAJ~TcJ]J..i ~uaSO]9iqI4,15 ~ i5~~ "!l7]-"-1 {!7(j£"'l]C'f%cJ]J..i:::: 691cJ]J..i 891cJ]
7~ {l ~%j.]li+ 'T-~'3' t1JJ..}{!..B..1iJ ~ %~ -t;}o:j
~ ~"!l ~~ "?:l Ilj-{! % Al]71-t;}o:j 63 %-"-1 %,-.g. "'~
~% ~ ~ ~ 'T- ~2..E£ 3j ~~ ~ 'T-~j.]li7}
~..B..i5}qI6,17. 'T-~'3' llJJ..}{!..B..IiJ::: lOOOcGY -"-1 5:J..}~ -t;}-c ?;!.o] '?1~3j2..£ o]?;!.::: 91-i'-llJJ..}
{! j.]li""] 3000cGY ~ 5:J..}i5}-c ?;!.:il}
it:::
ltJl}~ ~~
T
~JqJl ~q. Stage III 0]i5}-"-1:@A
cJ] J..i -c It.ll}~ 5!.?] ~ Stage IV :@-;:<.l-cJ] J..i -c "'~ ~
%0] 30%£ .=Iq;>;] ~;>;]
U
q l8 o]91cJ]s:. re- tinoic acid~ angiostatic agent~ TNP-4700] Al] C'f~. * *~~~~ %~£~~ .~~ ~~~
j,]lio1] RJl}7} ;Uq~ .Jil..Jl7]- ;U q I9,20 l31I- Metaiodobenzyulguanidine(13II-MIBG)* 0] %ii}~
~~£~~%~ Jl%~~ ~4~~4* *£~
Ii':! ~i>~~ ~7]* 7}~ ~7.}01]},~~ 50% ~s=.~
j,]li1L4* ~~ ;Uq21. ~~.£},~]~%~ j,]li~
j,] t-01] ~ N-myc oncogene amplification, Chromo- some Ip %~ Chromosome structural abnonnality, Ha-ras p21 protein~ ~ 7}~ lE ~:il}, Shimada cl- assification ~ unfavorable histology type %~ ~
~ oj] ~«l7.}9) '7t~ ~ ~, ~7] ~ 7] (I, II, IV -S), Favorable DNA ploidy
;=
~ ~,g. oj] ~«l7.} 9}ferritin, NSE, LDH ;=~
%0J:
lE «l7.}~ ~7} ~£01] u:te} j,]li<lJ~o] ~~so]~ 7;3~0]ql,2,12,22.
~~~~~~~ ~~:il} .Jil..~R~ ~ ~~~~
7;3i>J:0] ;U£oj, Jl~]~~o1JA~~ o]~~ .~R~
4 <lJ},}{iR~ 0] 4-7}~ q . ~ B "itA] {J ~ ~ ~ 7} ~£Ii':! ~~ .~R~ ~ ~~o] A]i>~~Jl
;U£oj, ~~~ Al]~5O].A] *~ %0J:~ <lJ},}{i j,]
li* A] i>~ ii}~ ~ ~~ 0]-61 ~ tumor specific antibody ~ retinoic acid 7} },}%50] 7] £ ~q.
~ ~To1]},~~ ~AJ~~ ~ ~t!0] ~ 7;3~~
2\1 },~ ~%o] 59.2 %, 5\1 ),~ ~%o] 29.6 % ~ ojl~7} 7.~~ii};1.Jl, °l~ 1J.l] °l~ ~B-'8 7;3~
7} 57%~ '\1':U-71 u:j]-lf-0]Jl EE~ ~B eJA]91 Stage III 0] AJo] 95 % 0] AJo] ~U] u:j]
-If-
0] e} Jl ),~z.t ~~ ;Uq. 1J.l] o]AJo1]},~~ ~,g. ~7]~ ojl~
~ u~~ ~~~ 20 %~s:.e}Jl .Jil..Jlso]Jl ;U q l,23.
Bessh04~ .Jil...Jl.so} Woods24
;= El
.Jil...Jlo1]}'i .Jil..qA]lIj j,]t-01] ~ ~~, *olo1]},~ VMA spot test.so}, VMA, HV A~ High perfonnance liquid chromato- graphy
;=
£~, ),~~ 67H-%! ~ °d 0}01]tJ1'iiH
~3..c1'<1
~ .A]i;~'ii}~ ~7101] ~{!i>H},~ j,]liW£~},~ 95 %0]AJ~ ~~ j,lli%4 ~71 ~71 ~B%
4 ~~ ~B%(1f7000-1/15000)~ ~Jl ;Uq2. 0]
.so} :Q-~ ~~~~ ~71~B4 ~3..c1'<1 ~ ~ii}
~ ~-2'>] j,]li~ .A]3}w£~~i
1:1"*
~~ oj]~~~~~ ;U~ ~o]q.
},1]~%01] ~ii}04 ~~, )'j ~ ~~, ~ 71, ~
B '3J
j,]li, ),~~%01] tJ1'ii}~ .Jil..Jlii};1.q. ~7]~~01]
},~~ ~~-:ii-01]},~ .Jil..Jl-'8 ~01] 1:I]ii}~ Stage IlI.so}
Stage 1V~ 1:1]%0] ~Jl °]01] u:te}},~ ),~~%£
7.1~ii}~q. u:t2.}}'i ~7]~t!:il} ~7]j,]li* 7]ii}
~ },~~%~ ~ii]~Ll] 9-?::jii}~o): ii}oj, N-myc
*~7.}~ ~~ %% 7,3},}'ii}~ oj]~~ 3ll-~4 j,]
li~ T~~}* 7]'ii}~ ~s:. ~Rii}q. ~%R~
0] ~ 01] £ ~
c 1
7}7.] j,]li ~ 0] A] s:.~ Jl ;U ~ ~ A]~o1]Ai -:ii-Y101]Ai2.}£ ~%R~~ %~Jl} j,]li llJ{J% ~ii}~ ~o] ~R~ u:j]7}so]Di, ~cl tJ1~Zl-~ %<>J~ llJ{Jo1] u:t2.} ~7.}* ~*ii}Jl j,]li ii}~ ~o] ~Rii}qJl ),~z.t-'8q.
1.
%::<J§j: %::<J§j
~o}Jl}(ed 6). 1997, Pp 913- 916 2. Katzenstein HM, Cohn SL: Advances in thediagnosis and treatment of neuroblastoma. Curr Opin Oncol 10(1):43-51, 1998
3. Marina NM: Diagnosis and treatment of the most common solid tumors in childhood. Ca- ncer Diag Treat 19(4), 871-889, 1992
4. Bessho F: Colloquy on neuroblastoma scre- ening. Med Pediatr Oncol 31(2):106-110, 1998 5. Matthay KK: Neuroblastoma, biology and th-
erapy. Oncology 11(12):1857-66, 1997
6. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson lB, Black CT, Gerbing R, Hasse GM, Stram DO, swift P, Lukens IN: Successful treatment of stage III neuroblastoma based on prospective biologic staging; a Children's Cancer Group Study. J Clin Oncol 16(4):1256-64,1998
7. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castel berry RP De Bernardi B, Evans AE, Favrot M, Hedborg Fl: Revision of the International Criteria for Neuroblastoma, J Clin Oncol 11(8):1466-1477,1993
8. al-Mulhim I: Neuroblastoma in children a IO-year experience in Saudi Arabia. J Trop Pediatr 44(2):77-80, 1998
9. Grazia E, Cimador M, Bernardi B: Recent advances on retroperitoneal neuroblastoma.
Arch Hal Urol Androl 69(4): 233-40, 1997 10. Marina NM: Biology and treatment of pe-
diatric malignant solid tumors. Cancer Che- mother BioI Res Modif 17:642-671, 1997 11. Katzenstein HM, Bowman LC, Brodeur GM,
Thorner PS, Joshi W, Smith El, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL: Prognostic significance of age, MYCN oncogene ampli- fication, tuinor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience-a pediatric oncology group study. J Clin Oncol 16(6):2007 -2017, 1998
12. Sawada T, Komatsu H, Shirai C, Yamamoto S, Ishiwari K, Ishida H, Olunizono Y, Ma- tsumura T: Neuroblastoma. Japan J Cancer and Chemother 22(1):28-36, 1995
13. Eguchi H, Takaue Y, Kawano Y, Watanabe A, Watanabe T, Kikuta A, Koizumi S, Ma- tsumura T, Sawada A, Horikoshi Y, Sekine Y, Koyama T, Shimokawa T, Shimizu K, Ka- wasaki K, Mugishima H, Takayama J, Ohira M, Ogawa M: Peripheral blood stem cell autografts for the treatment of children over 1 year old with stage IV neuroblastoma: a long-terrn follow-up. Bone Marr Transpl 21 (10) :1001-1004, 1998
14. Vassal G, Pondarre C, Cappelli C, Terrier-Lacombe MJ, Boland I, Morizet J, Benard J, Venuat AM, Ardouin P, Hartmann 0, Gouyette A: DNA topoisomerase I, a new target for the treatment of neuroblastoma.
Europ J Cancer 33(12):2011-2015, 1997 15. Choi SH, Tsuchida Y, Yang HW: Oral versus
intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice. Cancer Let 124:15-21, 1998
16. Kaneko M, Ohakawa H, Iwakawa M: Is ex- tensive surgery required for treatment of ad-
vanced neuroblastoma'! J Pediatr Surg 32(J 1):
1616-1619, 1997
17. Yokoyama 1, lkawa H, Endow M, Fuchimolo Y, Watanabe K, Hosoya R, Nishimura K.: The role of surgery in advanced neuroblastoma.
Europ J Pediatr Surg 5(1):23-6, 1995 . 18. Leavey PJ, Odom LF, Poole M, McNeely L,
Tyson RW, Haase GM: Intra-operative radi- ation therapy in pediatric neuroblastoma. Med Pediatr Oncol 28(6):424-8, 1997
19. Lovat PE, Irving H, Annicchiarico-Petruzzelli M, Bernassola F, Malcolm AJ, Pearson AD, Melino G, Redfern CP: Retinoids in neuro- blastoma therapy: distinct biological properties of 9-cis- and all-trans-retinoic acid. Europ J Cancer 33( 12):2075-80, 1997
20. Wassberg E, Christofferson R: Angiostatic tr- eatment of neuroblastoma. Europ J Cancer 33 (12):2020-3, 1997
21. Mastrangelo R, Tornesello A, Mastrangelo S:
Role of 13II-metaiodo benzyl guanidine in the treatment of neuroblastoma. Med Pediatr Oncol 31 (J ):22-6, J 998
22. Castel SV, Melero MC, Garcia RP, Navajas GA, Ruiz
n ,
Navarro FS, Garlin VC, Galbe SM: Neuroblastoma in children under than 1 year of age. Anal Espan Pediatr 47(6): 584-90,1997
23. Chamberlain RS, Auinones R, Dinndorf P, Movassaghi N, Goodstein M, Newman K:
Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma. Ann Surg Oncol 2(2):93-100,1995
24. Wood WG, Tuchman M, Bobison LL, Be- rnstein M, Lecierc JM, Brisson LC, Brossard J, Hill G, Shuster J, Luepker R, Byrne T, Weitzman S, Bunin G, Lemieux B: A population based study of the usefulness of screening for neuroblastoma. Lancet 348(9043):
1682-7,1996
- 63-
